Show simple item record

dc.contributor.authorFindling, Robert L.
dc.contributor.authorKafantaris, Vivian
dc.contributor.authorPavuluri, Mani
dc.contributor.authorMcNamara, Nora K.
dc.contributor.authorMcClellan, Jon
dc.contributor.authorFrazier, Jean A.
dc.contributor.authorSikich, Linmarie
dc.contributor.authorKowatch, Robert
dc.contributor.authorLingler, Jacqui
dc.contributor.authorFaber, Jon
dc.contributor.authorRowles, Brieana M.
dc.contributor.authorClemons, Traci E.
dc.contributor.authorTaylor-Zapata, Perdita
dc.date2022-08-11T08:10:28.000
dc.date.accessioned2022-08-23T17:10:12Z
dc.date.available2022-08-23T17:10:12Z
dc.date.issued2011-06-01
dc.date.submitted2012-05-31
dc.identifier.citationJ Child Adolesc Psychopharmacol. 2011 Jun;21(3):195-205. <a href="http://dx.doi.org/10.1089/cap.2010.0084" target="_blank">Link to article on publisher's site</a>
dc.identifier.issn1044-5463 (Linking)
dc.identifier.doi10.1089/cap.2010.0084
dc.identifier.pmid21663422
dc.identifier.urihttp://hdl.handle.net/20.500.14038/45999
dc.description.abstractOBJECTIVE: The primary goal of this exploratory study was to obtain data that could lead to evidence-based dosing strategies for lithium in children and adolescents suffering from bipolar I disorder. METHODS: Outpatients aged 7-17 years meeting Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic criteria for bipolar I disorder (manic or mixed) were eligible for 8 weeks of open label treatment with lithium in one of three dosing arms. In Arm I, participants began treatment at a dose of 300 mg of lithium twice daily. The starting dose of lithium in Arms II and III was 300 mg thrice daily. Patients in Arms I and II could have their dose increased by 300 mg/day, depending on clinical response, at weekly visits. Patients in Arm III also had mid-week telephone interviews after which they could also have their dose of lithium increased by 300 mg per day. Youths weighing I, whereas youths weighing >/=30 kg were randomly assigned to Arm I, II, or III. Randomization was balanced by age (7-11 years, 12-17 years) and sex in approximately equal numbers. A priori response criteria were defined as a Clinical Global Impressions-Improvement scale score of /= 50% improvement in Young Mania Rating Scale score, and more than half of the patients (58%) achieved response. Overall, lithium was well tolerated. All three treatment arms had similar effectiveness, side effect profiles, and tolerability of lithium. CONCLUSIONS: On the basis of these results, a dosing strategy in which pediatric patients begin lithium at a dose of 300 mg thrice daily (with an additional 300 mg increase during the first week), followed by 300 mg weekly increases until a priori stopping criteria are met, will be used in an upcoming randomized, placebo-controlled trial.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=21663422&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111866/pdf/cap.2010.0084.pdf
dc.subjectAdolescent
dc.subjectAntimanic Agents
dc.subjectBipolar Disorder
dc.subjectBody Weight
dc.subjectChild
dc.subjectDose-Response Relationship, Drug
dc.subjectEvidence-Based Medicine
dc.subjectFemale
dc.subjectHumans
dc.subjectLithium Carbonate
dc.subjectMale
dc.subjectSeverity of Illness Index
dc.subjectTreatment Outcome
dc.subjectPsychiatry
dc.titleDosing strategies for lithium monotherapy in children and adolescents with bipolar I disorder
dc.typeJournal Article
dc.source.journaltitleJournal of child and adolescent psychopharmacology
dc.source.volume21
dc.source.issue3
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1520&amp;context=psych_pp&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/psych_pp/521
dc.identifier.contextkey2924411
refterms.dateFOA2022-08-23T17:10:13Z
html.description.abstract<p>OBJECTIVE: The primary goal of this exploratory study was to obtain data that could lead to evidence-based dosing strategies for lithium in children and adolescents suffering from bipolar I disorder.</p> <p>METHODS: Outpatients aged 7-17 years meeting Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic criteria for bipolar I disorder (manic or mixed) were eligible for 8 weeks of open label treatment with lithium in one of three dosing arms. In Arm I, participants began treatment at a dose of 300 mg of lithium twice daily. The starting dose of lithium in Arms II and III was 300 mg thrice daily. Patients in Arms I and II could have their dose increased by 300 mg/day, depending on clinical response, at weekly visits. Patients in Arm III also had mid-week telephone interviews after which they could also have their dose of lithium increased by 300 mg per day. Youths weighing I, whereas youths weighing >/=30 kg were randomly assigned to Arm I, II, or III. Randomization was balanced by age (7-11 years, 12-17 years) and sex in approximately equal numbers. A priori response criteria were defined as a Clinical Global Impressions-Improvement scale score of /= 50% improvement in Young Mania Rating Scale score, and more than half of the patients (58%) achieved response. Overall, lithium was well tolerated. All three treatment arms had similar effectiveness, side effect profiles, and tolerability of lithium.</p> <p>CONCLUSIONS: On the basis of these results, a dosing strategy in which pediatric patients begin lithium at a dose of 300 mg thrice daily (with an additional 300 mg increase during the first week), followed by 300 mg weekly increases until a priori stopping criteria are met, will be used in an upcoming randomized, placebo-controlled trial.</p>
dc.identifier.submissionpathpsych_pp/521
dc.contributor.departmentDepartment of Psychiatry
dc.source.pages195-205


Files in this item

Thumbnail
Name:
cap.2010.0084_1_.pdf
Size:
205.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record